EU SGLT2 Inhibitor Market Analysis

$3,000.00$7,500.00

  • Type: Common Disease Area
  • Published : January 2022
  • Region: Europe
  • Country: Other
  • Report ID : 4995

  • Format: PPT, PDF

EU SGLT2 Inhibitor Market Analysis: Segmented by Drug Class, Country – Growth, Market Size, Future Prospects & Competitive Analysis, 2020 – 2028

Clear

Report Description of the EU SGLT2 Inhibitor Market Analysis

Research Scope and Assumption

  • The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)
  • The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis
  • We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses
  • All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis
  • Inflation has not been accounted for in order to estimate and forecast the market
  • Numbers may not add up due to rounding off

Reason to buy the report:

  • Facilitate decision-making based on strong current and forecast data for EU SGLT2 Inhibitor Market Analysis
  • Develop strategies based on the latest regulatory framework
  • Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market
  • Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the EU SGLT2 Inhibitor Market Analysis
  • Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders
  • To strategically profile key players and comprehensively analyze their market shares and core competencies
  • We have technically sound team which do a deep dive research and also provide strategy based consulting analysis

EU SGLT2 Inhibitor Market Analysis Executive Summary

SGLT2 inhibition effectively lowers blood glucose levels and also accords other benefits, such as weight loss, low incidence of hypoglycaemia, and reduction in blood pressure. SGLT2 inhibitor is the newest addition into the armamentarium to treat Type-2 Diabetes. Kidney plays a very important role in glucose homeostasis by regulating gluconeogenesis, glucose uptake from the circulation, and glucose reabsorption from the urine filtered in the renal glomeruli.

Market Size and Key Findings

The EU SGLT2 Inhibitor Market Analysis size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 17% during the forecast period.

The size of the SGLT2 Inhibitor Market in the Europe is predicted to be growing at a CAGR of 17% from 2021 to 2028.

Market Dynamics

Market Growth Drivers Analysis

The exponential growth of diabetic population YoY, especially type 2 diabetic patients, new innovative drugs are coming up in the market to increase the ease of access to the patients. With the increase in diabetic population, the need and demand for diabetes drugs are expected to increase. The other factors, such as better adoption than other therapies and government initiatives, are driving the diabetes drugs market.

Market Restraints

The older patient group and clinical inertia are the main barriers to initiate SGLT2i for eligible patients. Clinicians should change the glucocentric approach and focus on reducing renal events in T2D.

Competitive Landscape

Key Players

Company Coverage: –

  • Eli Lilly
  • Janssen Pharmaceuticals
  • Boehringer Ingelheim
  • AstraZeneca
  • Bristol Myers Squibb

Products in Pipeline

  • A handful of SGLT2 inhibitors have been approved for the treatment of type 2 diabetes or are currently undergoing clinical trials. Currently there are three SGLT2 selective inhibitors approved by the Food and Drug Administration (FDA) for mono, dual, and triple therapy: canagliflozin (Invokana®), dapagliflozin (Farxiga®) and empagliflozin (Jardiance®)

Notable Recent Deals

EU approval should give AZ and BMS first-to-market advantage over other companies developing SGLT2 inhibitors, notably Johnson & Johnson’s canagliflozin and Boehringer Ingelheim/Eli Lilly’s empagliflozin. Canagliflozin was filed for approval in the US in June, while empagliflozin is scheduled for regulatory submissions during 2013.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

On 25 February 2016, the European Medicines Agency (EMA) confirmed recommendations1 to minimise the risk of diabetic ketoacidosis in patients taking SGLT2 inhibitors (a class of type 2 diabetes medicines).

Diabetic ketoacidosis is a serious complication of diabetes caused by low insulin levels. Rare cases of this condition, including life-threatening ones, have occurred in patients taking SGLT2 inhibitors for type 2 diabetes and a number of these cases have been atypical, with patients not having blood sugar levels as high as expected.

An atypical presentation of diabetic ketoacidosis can delay diagnosis and treatment. Healthcare professionals should therefore consider the possibility of ketoacidosis in patients taking SGLT2 inhibitors who have symptoms consistent with the condition even if blood sugar levels are not high.

Following a review of the cases, EMA recommended updating the product information of SGLT2 inhibitors to list diabetic ketoacidosis as a rare adverse reaction (affecting up to 1 in 1,000 patients).

Patients taking these medicines should be aware of the symptoms of diabetic ketoacidosis, including rapid weight loss, nausea or vomiting, stomach pain, excessive thirst, fast and deep breathing, confusion, unusual sleepiness or tiredness, a sweet smell to the breath, a sweet or metallic taste in the mouth, or a different odour to urine or sweat. Patients should contact a doctor or the nearest hospital straightaway if they have any of these symptoms.

If diabetic ketoacidosis is suspected or confirmed, treatment with SGLT2 inhibitors should be stopped immediately and should not be re-started unless another cause for the ketoacidosis is identified and resolved.

Healthcare professionals should exercise caution with SGLT2 inhibitors in patients with risk factors for ketoacidosis and inform patients of these factors. These include low insulin-producing capacity in the pancreas, a sudden drop in a patient’s insulin dose, increased insulin requirement (due to illness, surgery or alcohol abuse) or conditions that can restrict food intake or lead to severe dehydration.

1. Report Description of the EU SGLT2 Inhibitor Market Analysis
1.1 Research Scope and Assumption
1.2 Objective of the study
1.3 Research Methodology
1.4 Reason to buy the report
2. EU SGLT2 Inhibitor Market Analysis Executive Summary
2.1 EU SGLT2 Inhibitor Market Analysis – Industry Snapshot & key buying criteria, 2020-2028
2.2 Market Size, Growth Prospects and Key findings
3. Market Dynamics of EU SGLT2 Inhibitor Market Analysis
3.1 Market Growth Drivers Analysis
3.1.1 The exponential growth of diabetic population YoY
3.1.2 New innovative drugs in the market
3.2 Market Restraints Analysis
3.2.1 The older patient group
3.2.2 Clinical inertia
4. EU SGLT2 Inhibitor Market Segmentation
4.1 By Drug Class:
4.1.1 Sodium-dependent Glucose Cotransport 2 (SGLT-2) Inhibitor
• Invokana (Canagliflozin)
• Jardiance (Empagliflozin)
• Farxiga/Forxiga (Dapagliflozin)
• Suglat (Ipragliflozin)
4.2 By Country:
4.2.1 France
4.2.2 Germany
4.2.3 Italy
4.2.4 Spain
4.2.5 UK
4.2.6 Russia
4.2.7 Rest of EU
5. EU SGLT2 Inhibitor Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6. Competitive Landscape
6.1 Major Top Market Players
6.2 Products in Pipeline
6.3 R&D Initiatives in SGLT-2 Market
6.4 Notable recent deals in SGLT-2 Market
6.4.1 Joint Ventures
6.4.2 Partnerships
6.4.3 Mergers & Acquisitions
6.4.4 Strategic divestments
7. Key Company Profiles
7.1 Eli Lilly Company overview
Product & Services, Strategies & Financials
7.2 Janssen Pharmaceuticals Company overview
Product & Services, Strategies & Financials
7.3 Boehringer Ingelheim Company overview
Product & Services, Strategies & Financials
7.4 AstraZeneca Company overview
Product & Services, Strategies & Financials
7.5 Bristol Myers Squibb Company overview
Product & Services, Strategies & Financials
8. Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
9. Factors Driving Future Growth
9.1 New Trends and Development of SGLT-2 market
9.2 Future Opportunities
10. Strategic Recommendations

EU SGLT2 Inhibitor Market Analysis Segmentation

By Drug Class:

Jardiance has the highest growth among all the drugs in the SGLT2 class, in terms of revenue, with an expected CAGR of about 22.51%, during the forecast period. Jardiance was reported to have less cardiovascular risk among other oral drugs. Jardiance is a once-daily oral medication that is used to control blood glucose levels in people with type 2 diabetes.

By Country:

The Europe Sodium-dependent Glucose Cotransporter 2 (SGLT – 2) Market report quantifies the market share held by the significant players of the industry and gives an in-depth view of the competitive landscape. This market is classified into different segments with a comprehensive analysis of each with respect to a geography for the research period.  

Research Methodology

Insights10 will provide you reports within 10 key parameters which are:

  1. Market overview
  2. Market growth drivers & restraints
  3. Epidemiology or disease type
  4. Market segmentation
  5. Market share
  6. Competitive landscape
  7. Key company profiles
  8. Healthcare policies & regulatory framework
  9. Reimbursement scenario
  10. Factors driving future growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision making for business stakeholders. Our focused approach to develop reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

Our analysis methodology involves three critical stages:

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers and researchers across countries through which we engage with local experts to gather key data points and assumptions around each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain the high level of accuracy and consistency. The market data is analysed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, market share as well as segment-level analysis of the specific market. Our report includes precise, to the point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

  • Statistical Databases
  • Company Websites/Annual Reports
  • Trade Publications
  • Online Databases
  • Published Research Reports
  • Whitepapers
  • Press Releases of Key Market Players

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameter and micro indicators. The macro parameters includes changes in government policies, demand and supply of the market, government intervention programs and major market share. The micro indicators GDP growth, market size, market volume etc. We also understand nuances specific to each country like US, Canada, India, Germany, etc. and have worked across 60+ countries and hence no only understand global trends, but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. start with large overall market and segment different areas and bottom-up approach i.e. start with population and epidemiology and roll up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach mainly used for new product forecasting and bottom-up approach is used for demand estimation of any product for different countries summed up to form total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and Africa for the period of 2020 to 2028. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape and policy and regulatory scenario and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases and the company level averages etc.

We make sure to finalize the numbers in alignment to the market research. Firstly, our internal experts ensure thorough validation and checking to ensure the accurate and precise analysis and then validation is also done using multiple data analysis model.  Two level validation is done and entails finalization of report scope and to way of representation pattern.

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analysed and synthesized. A second series of interviews are done if necessary to check and validate. The future opportunities are analysed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results are then, interpreted by considering following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue / volume
  • Analyzing current needs and determining penetration to estimate market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and its impact to the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumptions.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy this report, please complete the form below.

    We value your inquiry and offer free customization with every report to fulfil your exact research needs.

    This website is secure and your personal details are safe.



    This report addresses

    • Market intelligence to enable effective decision making
    • Growth opportunities and trend analysis
    • Competitive benchmarking
    • Historical data & forecasts
    • Regional opportunities

    Need more?

    • Speak to our analyst to know how this research was put together
    • Add more countries or regions as part of customisation
    • Understand how this report can have direct impact on your revenue

    Get a custom report based on your requirements